Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, Lene Dreyer, Annette Hansen, Ib Tønder Hansen, Gina Birgitte Kollerup, Louise Linde, Hanne Merete Lindegaard, Uta Engling Poulsen, Annette Schlemmer, Dorte Vendelbo Jensen, Signe Jensen, Gisela Hostenkamp, Mikkel Østergaard, All Departments of Rheumatology in Denmark

491 Citationer (Scopus)

Abstract

To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.
OriginalsprogEngelsk
TidsskriftArthritis & Rheumatism
Vol/bind62
Udgave nummer1
Sider (fra-til)22-32
Antal sider11
ISSN0004-3591
DOI
StatusUdgivet - 1 jan. 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry'. Sammen danner de et unikt fingeraftryk.

Citationsformater